#BEGIN_DRUGCARD DB01066

# AHFS_Codes:
Not Available

# ATC_Codes:
J01DD16

# Absorption:
Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases. Under fasting conditions, the estimated absolute bioavailability of cefditoren pivoxil is approximately 14%. The absolute bioavailability of cefditoren pivoxil administered with a low fat meal (693 cal, 14 g fat, 122 g carb, 23 g protein) is 16.1 &plusmn; 3.0%.

# Biotransformation:
Hydrolysis of cefditoren pivoxil to its active component, cefditoren, results in the formation of pivalate. Cefditoren is not appreciably metabolized.

# Brand_Mixtures:
Not Available

# Brand_Names:
Meiact
Spectracef

# CAS_Registry_Number:
117467-28-4

# ChEBI_ID:
59343

# Chemical_Formula:
C19H18N6O5S3

# Chemical_IUPAC_Name:
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Cefditoren is a third-generation cephalosporin antibiotic for oral use. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Anti-Bacterial Agents
Cephalosporins

# Drug_Interactions:
Cimetidine	H2-Antagonists such as cimetidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
Esomeprazole	Proton pump inhibitors such as esomeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
Famotidine	H2-Antagonists such as famotidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
Lansoprazole	Proton pump inhibitors such as lansoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
Nizatidine	H2-Antagonists such as nizatidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
Omeprazole	Proton pump inhibitors such as omeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
Pantoprazole	Proton pump inhibitors such as pantoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
Rabeprazole	Proton pump inhibitors such as rabeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
Ranitidine	H2-Antagonists such as ranitidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.

# Drug_Reference:
20566418	Tempera G, Furneri PM, Carlone NA, Cocuzza C, Rigoli R, Musumeci R, Pilloni AP, Prenna M, Tufano MA, Tullio V, Vitali LA, Nicoletti G: Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren. J Chemother. 2010 Jun;22(3):153-9.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Soluble at levels equal to < 0.1 mg/mL.

# Food_Interactions:
Antacids may reduce the serum concentration of cefditoren. Consider alternative methods to minimize/control acid reflux. If use of antacids cannot be avoided, separate administration by at least several hours to reduce chance of interaction

# GenBank_ID:
Not Available

# Generic_Name:
Cefditoren

# HET_ID:
Not Available

# Half_Life:
Mean terminal elimination half-life is 1.6 &plusmn; 0.4 hours in young healthy adults.

# InChI_Identifier:
InChI=1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1

# InChI_Key:
InChIKey=KMIPKYQIOVAHOP-YLGJWRNMSA-N

# Indication:
For the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D01628

# LIMS_Drug_ID:
1066

# Mechanism_Of_Action:
The bactericidal activity of cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefditoren is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases.

# Melting_Point:
127-129 Â°C

# Molecular_Weight_Avg:
506.578

# Molecular_Weight_Mono:
506.050079786

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/spe1677.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164747187

# Pharmacology:
Cefditoren pivoxil is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active cefditoren. Cefditoren is a cephalosporin with antibacterial activity against gram-positive and gram-negative pathogens. Cefditoren is effective against <i>Staphylococcus aureus</i> (methicillin-susceptible strains, including b-lactamase-producing strains), penicillin-susceptible strains of <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i>, <i>Streptococcus pyogenes</i>, <i>Haemophilus influenzae</i> (including b-lactamase-producing strains), <i>Haemophilus parainfluenzae</i> (including b-lactamase-producing strains), <i>Moraxella catarrhalis</i> (including b-lactamase-producing strains), <i>Streptococcus agalactiae</i>, <i>Streptococcus</i> Groups C and G, and <i>Streptococcus</i>, viridans group (penicillin-susceptible and -intermediate strains).

# Predicted_LogP_Hydrophobicity:
1.7

# Predicted_LogS:
-4.1

# Predicted_Water_Solubility:
4.41e-02 g/l

# Primary_Accession_No:
DB01066

# Protein_Binding:
Binding of cefditoren to plasma proteins averages 88% from <i>in vitro</i> determinations, and is concentration-independent at cefditoren concentrations ranging from 0.05 to 10 mg/mL.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/spectracef.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00850

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
CDTR-PI
Cefditoren Pivaloyloxymethyl Ester
Cefditoren Pivoxil

# Synthesis_Reference:
Not Available

# Toxicity:
Information on cefditoren pivoxil overdosage in humans is not available. However, with other b-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. In acute animal toxicity studies, cefditoren pivoxil when tested at the limit oral doses of 5100 mg/kg in rats and up to 2000 mg/kg in dogs did not exhibit any health effects of concern.

# Update_Date:
2013-02-08 16:19:52 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Cefditoren

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17724158	Yamada M, Watanabe T, Miyara T, Baba N, Saito J, Takeuchi Y, Ohsawa F: Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7. Epub 2007 Aug 27.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X16022

# Drug_Target_1_GenBank_ID_Protein:
984233

# Drug_Target_1_GeneCard_ID:
penA

# Drug_Target_1_Gene_Name:
penA

# Drug_Target_1_Gene_Sequence:
>2040 bp
ATGAGAAAATTTAACAGCCATTCGATTCCGATTCGGCTTAATTTATTGTTTTCAATCGTC
ATTTTACTCTTTATGACCATTATTGGTCGTTTGTTGTATATGCAGGTTTTCAACAAGGAT
TTTTACGAAAAAAAGCTAGCCTCAGCTAGTCAGACCAAGATTACAAGCAGTTCAGCCCGT
GGGGAAATTTATGATGCTAGTGGAAAACCTTTGGTAGAAAATACGTTAAAGCAGGTTGTT
TCCTTTACGCGTAGCAATAAAATGACGGCTACAGACTTAAAAGAAACAGCTAAAAAGTTA
CTGACTTATGTGAGCATCAGTTCTCCAAATTTGACAGAACGAGCTGGCGATTACTATTTG
GCTGATCCTGAAATCTATAAAAAAATAGTGGAAGCTCTCCCAAGCGAGAAACGCTTGGAT
TCAGATGGCAATCGTCTATCCGAATCAGAACTGTATAACAATGCGGTCGATAGTGTACAA
ACGAGTCAACTAAACTATACAGAGGATGAAAAGAAAGAAATCTATCTTTTTAGTCAGTTA
AATGCTGTTGGAAACTTTGCGACAGGAACCATTGCTACAGATCCTCTAAATGATTCTCAG
GTGGCTGTTATTGCCTCTATTTCAAAGGAGATGCCTGGCATTAGTATTTCTACTTCTTGG
GATAGAAAGGTTTTGGAAACTTCCCTTTCTTCTATAGTTGGGAGTGTATCCAGTGAAAAA
GCTGGTCTCCCAGCGGAAGAAGCAGAAGCCTATCTTAAAAAAGGCTATTCTCTAAATGAC
CGTGTAGGAACCTCCTATTTGGAAAAGCAATATGAAGAGACCTTACAAGGAAAACGCTCG
GTAAAAGAAATCCATCTGGATAAATATGGCAATATGGAAAGCGTGGATACAATTGAGGAA
GGTAGTAAGGGAAACAATATCAAACTGACCATTGATTTGGCTTTCCAAGATAGCGTGGAT
GCTTTACTGAAAAGTTATTTCAATTCTGAGCTAGAAAATGGTGGAGCCAAGTATTCTGAA
GGTGTCTATGCAGTCGCCCTTAACCCAAAAACAGGTGCGGTTTTGTCTATGTCAGGGATT
AAACATGACTTGAAAACGGGAGAGTTGACGCCTGATTCCTTGGGAACGGTAACCAATGTC
TTTGTTCCAGGTTCGGTTGTCAAGGCGGCGACCATCAGCTCAGGTTGGGAAAATGGAGTC
TTGTCAGGAAACCAGACCTTGACAGACCAGTCCATTGTCTTCCAAGGTTCAGCTCCCATC
AATTCTTGGTATACTCAGGCTTACGGTTCATTCCCTATCACAGCGGTCCAAGCTCTGGAG
TATTCATCAAATACCTATATGGTCCAAACAGCCTTAGGTCTTATGGGGCAAACCTATCAA
CCCAATATGTTTGTCGGCACCAGCAATCTAGAGTCTGCTATGGAGAAACTGCGTTCAACC
TTTGGCGAATATGGCTTGGGTACTGCGACAGGAATTGACCTACCAGATGAATCTACTGGA
TTTGTTCCCAAAGAGTATAGCTTTGCTAATTACATTACTAATGCCTTTGGGCAGTTTGAT
AACTATACGCCGATGCAGTTGGCTCAGTATGTAGCAACTATTGCAAATAATGGTGTTCGT
GTGGCTCCTCGTATTGTTGAAGGCATTTATGGTAATAATGATAAGGGAGGACTGGGTGAC
TTGATTCAGCAACTGCAACCGACAGAGATGAATAAGGTCAATATATCCGACTCCGATATG
AGCATCTTGCACCAAGGTTTTTATCAGGTTGCCCATGGTACTAGTGGATTGACAACTGGA
CGTGCCTTTTCAAATGGTGCCTTGGTATCCATTAGCGGAAAAACAGGTACAGCCGAAAGC
TATGTGGCAGATGGTCAGCAAGCAACCAATACCAATGCGGTGGCCTATGCCCCATCTGAT
AATCCCCAAATCGCTGTCGCAGTGGTCTTTCCTCATAATACCAATCTAACAAATGGTGTA
GGACCTTCCATTGCGCGTGACATTATCAATCTGTATCAAAAATACCATCCAATGAACTAG

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
11544234	Hoskins J, Alborn WE Jr, Arnold J, Blaszczak LC, Burgett S, DeHoff BS, Estrem ST, Fritz L, Fu DJ, Fuller W, Geringer C, Gilmour R, Glass JS, Khoja H, Kraft AR, Lagace RE, LeBlanc DJ, Lee LN, Lefkowitz EJ, Lu J, Matsushima P, McAhren SM, McHenney M, McLeaster K, Mundy CW, Nicas TI, Norris FH, O'Gara M, Peery RB, Robertson GT, Rockey P, Sun PM, Winkler ME, Yang Y, Young-Bellido M, Zhao G, Zook CA, Baltz RH, Jaskunas SR, Rosteck PR Jr, Skatrud PL, Glass JI: Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol. 2001 Oct;183(19):5709-17.
2654541	Dowson CG, Hutchison A, Spratt BG: Extensive re-modelling of the transpeptidase domain of penicillin-binding protein 2B of a penicillin-resistant South African isolate of Streptococcus pneumoniae. Mol Microbiol. 1989 Jan;3(1):95-102.
2798106	Dowson CG, Hutchison A, Spratt BG: Nucleotide sequence of the penicillin-binding protein 2B gene of Streptococcus pneumoniae strain R6. Nucleic Acids Res. 1989 Sep 25;17(18):7518.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6121

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
73872.3

# Drug_Target_1_Name:
Penicillin-binding protein 2B

# Drug_Target_1_Number_of_Residues:
680

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer

# Drug_Target_1_Protein_Sequence:
>Penicillin-binding protein 2B
MRKFNSHSIPIRLNLLFSIVILLFMTIIGRLLYMQVLNKDFYEKKLASASQTKITSSSAR
GEIYDASGKPLVENTLKQVVSFTRSNKMTATDLKETAKKLLTYVSISSPNLTERQLADYY
LADPEIYKKIVEALPSEKRLDSDGNRLSESELYNNAVDSVQTSQLNYTEDEKKEIYLFSQ
LNAVGNFATGTIATDPLNDSQVAVIASISKEMPGISISTSWDRKVLETSLSSIVGSVSSE
KAGLPAEEAEAYLKKGYSLNDRVGTSYLEKQYEETLQGKRSVKEIHLDKYGNMESVDTIE
EGSKGNNIKLTIDLAFQDSVDALLKSYFNSELENGGAKYSEGVYAVALNPKTGAVLSMSG
IKHDLKTGELTPDSLGTVTNVFVPGSVVKAATISSGWENGVLSGNQTLTDQSIVFQGSAP
INSWYTQAYGSFPITAVQALEYSSNTYMVQTALGLMGQTYQPNMFVGTSNLESAMEKLRS
TFGEYGLGTATGIDLPDESTGFVPKEYSFANYITNAFGQFDNYTPMQLAQYVATIANNGV
RVAPRIVEGIYGNNDKGGLGDLIQQLQPTEMNKVNISDSDMSILHQGFYQVAHGTSGLTT
GRAFSNGALVSISGKTGTAESYVADGQQATNTNAVAYAPSDNPQIAVAVVFPHNTNLTNG
VGPSIARDIINLYQKYHPMN

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P0A3M6

# Drug_Target_1_SwissProt_Name:
PBP2_STRR6

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
4.85

# Drug_Target_1_Transmembrane_Regions:
9-29

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
15308278	Martin SI, Kaye KM: Beta-lactam antibiotics: newer formulations and newer agents. Infect Dis Clin North Am. 2004 Sep;18(3):603-19, ix.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
BA000016

# Drug_Target_2_GenBank_ID_Protein:
18145626

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
pbpA

# Drug_Target_2_Gene_Sequence:
>2040 bp
ATGACTGAAAGAAAAAGAGAGCATAAAGATAGAAAGCAGAATAAAAATTCACCTAAAAAT
CAATCGAAAGTAACAAAATTTTTGAAATGGTTCTTTATAGGGATTCTGCTTCTAGGGATA
ACTGCCGTAACAGTAGTTGGAATTTACGTTCTTTCTATTATACGTTCATCTCCAGAGTTA
GATGTTCAGGCAATTCAATCTCTAAATCAGCCATCCATTCTTTACGATGATCAGGGAAAC
TTTATGGATAATGTTATAACTCGTGAACAACGTTATGTAGTTAAATCTGAAGAGATACCT
GATAACTTAAAAAAGGCTTTTGTAGCTATTGAAGACGAAAGATTTTATGAGCATAAAGGA
ATAGACATTAAAAGAATTTTTGGGGTAATAGCTTCTAATATTAAAGGTAAACTTTCAGGA
AGTAATACAGTTCAAGGGGCTTCAACCATAACTCAGCAACTTATAAAAAATGCCGTACTT
ACTAATGAAGTTAGTTATGAAAGAAAAATTAAAGAAATGTACTTAGCTTTGGAATTAGAA
AAGCACCTTTCAAAAGATGAAATCCTTACTACGTATTTAAATACAATTCCTATGGGTGGA
TACCAATATGGGGTTAGCGCAGCTGCTCAAAGATTTTTTAGTAAGAATGTTTCAGATTTG
AATTTAGTTGAGTGCGCTTATTTAGGAGGACTTACTCAAGCACCAACTTCTTATGATGGT
CTTTCAGAAGCAAATAAAGAAAATCCAAGTAGATATTTAAATAGAACTAAATCTGTACTA
TTTAAAATGCATGAACTTGGATATATTTCAAGTGAACAATATAATGACGCAATAAATGAA
ATTGACACAAATGGTATAAAATTCACACCAAATAATAAATTAAGTAAAACTAACTTTGAG
TGGTTCACAAGACCAGCTATAACTCAAGTTAAACAAGACTTAATGGATAAATATAAATAT
ACACAAGAGGAAGTTGACAAACTTATAGCTAATGGTGGATTAAAAATCTATACTTCAATG
GATAGAAATCTTCAAAATAATGTTCAAAAAGTTTTAGATGATCCAAATAACTATAAAGCT
ATAACTAATAATCCTAATGAAAAAAATGAAGATGGTGTTTATAAATTACAAGCATCTGCC
ACAATAATAGACTATAAAACAGGCCATGTTAAGGCTTTAGTTGGAGGAAGAGGGGAACAA
CCTGCTATGTCTCACAATAGAGCTTATTATGATTTAAAATCTATAGGTTCTGCAACAAAA
CCATTAACAGTTTATGGTCCTGCTATTGATTTAGGACTTGGTGGCGCTGGCTCTGTAGTA
AATGATTCTCCATTAAGTAATAAAGAGTTATCTTCTACAGGATATAAAGATCAACCTAAG
AATGAATACAATAGTTATAGAGGCCCTTTAACTTTTAGAGAAGCAATTAAAATCTCTAGT
AACTTAGCAGCCATAAAAGTTGCTAATGAAGTAGGTGTTTCAAACTCTATAGCTTATGGA
GAAAAATTAGGTCTTGTTTATGGACCTCATTCTAGAGGTATTTCCACAACAGCCTTAGGT
CAATTCCAAAATGACCCTAATAATCCTGATGGAGGAAATACTTATACTCTAGCTTCAGCC
TTCGGTGTTTTTGGTAATAACGGTGTTAAAACAAATGCTAAATTATATACAAAGGTATTA
GATTCTCATGGAAATGTAATTCTTGATACAAGTACTCCAGAAGAAACTAAAATATTTAGT
CCTCAAGCGTCTTATATAGTTTATGATATGCTTAAGGATCAAGTAGAAAGTGGCTCTGCA
AAATCTGCTAAATTTGGTAATATTCCTGTGGCGGGTAAAACAGGAACTACTACTGGAGAT
AAAGACTATTTATTTGCAGGATTAACTCCATATTATTCTGCGGCTATTTGGATTGGATAT
GATAAGCCTAGAGAAATGAGAACTAGTAGTGGTACTGTTACCTCTCCTATTTTCGGAAAA
ATAATGGGCTTAGCTCATAAAGACTTACAGTACAAAGAGGTTGACAACCTAGTGGAATAA

# Drug_Target_2_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_2_General_References:
11792842	Shimizu T, Ohtani K, Hirakawa H, Ohshima K, Yamashita A, Shiba T, Ogasawara N, Hattori M, Kuhara S, Hayashi H: Complete genome sequence of Clostridium perfringens, an anaerobic flesh-eater. Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):996-1001. Epub 2002 Jan 15.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
633

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
75178

# Drug_Target_2_Name:
Penicillin-binding proteins 1A/1B

# Drug_Target_2_Number_of_Residues:
679

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00905	Transpeptidase
PF00912	Transgly

# Drug_Target_2_Protein_Sequence:
>Penicillin-binding proteins 1A/1B
MTERKREHKDRKQNKNSPKNQSKVTKFLKWFFIGILLLGITAVTVVGIYVLSIIRSSPEL
DVQAIQSLNQPSILYDDQGNFMDNVITREQRYVVKSEEIPDNLKKAFVAIEDERFYEHKG
IDIKRIFGVIASNIKGKLSGSNTVQGASTITQQLIKNAVLTNEVSYERKIKEMYLALELE
KHLSKDEILTTYLNTIPMGGYQYGVSAAAQRFFSKNVSDLNLVECAYLGGLTQAPTSYDG
LSEANKENPSRYLNRTKSVLFKMHELGYISSEQYNDAINEIDTNGIKFTPNNKLSKTNFE
WFTRPAITQVKQDLMDKYKYTQEEVDKLIANGGLKIYTSMDRNLQNNVQKVLDDPNNYKA
ITNNPNEKNEDGVYKLQASATIIDYKTGHVKALVGGRGEQPAMSHNRAYYDLKSIGSATK
PLTVYGPAIDLGLGGAGSVVNDSPLSNKELSSTGYKDQPKNEYNSYRGPLTFREAIKISS
NLAAIKVANEVGVSNSIAYGEKLGLVYGPHSRGISTTALGQFQNDPNNPDGGNTYTLASA
FGVFGNNGVKTNAKLYTKVLDSHGNVILDTSTPEETKIFSPQASYIVYDMLKDQVESGSA
KSAKFGNIPVAGKTGTTTGDKDYLFAGLTPYYSAAIWIGYDKPREMRTSSGTVTSPIFGK
IMGLAHKDLQYKEVDNLVE

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Q8XJ01

# Drug_Target_2_SwissProt_Name:
PBPA_CLOPE

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
9.09

# Drug_Target_2_Transmembrane_Regions:
30-52

#END_DRUGCARD DB01066
